|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ETV6: a versatile player in leukemogenesis.
|
15826831 |
2005 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis.
|
26584717 |
2015 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both abnormalities affect the reciprocal RUNX1-ETV6 fusion product which could either eliminate or amplify its expression and thus contribute to leukemogenesis.
|
23077088 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The contribution of ETV6 to leukemogenesis occurs through different mechanisms that involve either its helix-loop-helix dimerization domain or its E26 transformation-specific (ETS) DNA-binding domain.
|
9454771 |
1998 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The absence of the reciprocal NCOA2-ETV6 transcript in one of the cases suggests that the ETV6-NCOA2 chimeric protein and not the reciprocal NCOA2-ETV6 is responsible for leukemogenesis.
|
18281529 |
2008 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene expression profiling provided evidence that leukemia in twins harbours the same subtype-typical feature as TEL-AML1-positive leukemia in singletons suggesting that the leukemogenesis model might also be applicable generally.
|
15356660 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nevertheless, functional studies would be needed to establish the biological role of AIF1L-ETV6 and ABL1-AIF1L and to determine whether they contribute to leukemogenesis and/or to the final leukemia phenotype.
|
29726059 |
2018 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify novel genes that cooperate with ETV6-RUNX1 in leukemogenesis, we generated a mouse model that uses the endogenous Etv6 locus to coexpress the Etv6-RUNX1 fusion and Sleeping Beauty transposase.
|
21628403 |
2011 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Translocation t(12;21), resulting in the ETV6-RUNX1 (or TEL-AML1) fusion protein, is present in 25% of pediatric patients with B-cell precursor acute lymphoblastic leukemia and is considered a first hit in leukemogenesis.
|
30381299 |
2019 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of a novel fusion gene, TTL, fused to ETV6 in acute lymphoblastic leukemia with t(12;13)(p13;q14), and its implication in leukemogenesis.
|
12764377 |
2003 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have recently reported that ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive ALL suggesting a direct role of IGF2BP1 in ETV6/RUNX1-mediated leukemogenesis.
|
27239736 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This cell line will be very useful in studying the different mechanisms by which alterations of ETV6 contribute to leukemogenesis and in testing the hypothesis that ETV6 might act as a tumor suppressor gene.
|
9087565 |
1997 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TEL-AML1 hybrid protein thought to be critical in leukemogenesis possesses the HLH domain of TEL fused to almost the entire AML1 protein, although the detailed mechanisms of leukemogenesis remain obscure.
|
9498702 |
1997 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we addressed the role of MN1-TEL in myeloid leukemogenesis using the same mouse model.
|
16105979 |
2005 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-TCR signaling synergizes with TEL-JAK2 to transform immature thymocytes and initiate leukemogenesis as shown by (1) the delayed leukemia onset in Rag2-, CD3epsilon- and pTalpha-deficient mice, (2) the occurrence of recurrent chromosomal alterations in pre-TCR-deficient leukemia, and (3) the correction of delayed leukemia onset in Rag2-deficient TEL-JAK2 mice by an H-Y TCRalphabeta transgene that mimics pre-TCR signaling.
|
17192390 |
2007 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
EPOR mRNA is selectively and ectopically expressed in ETV6-RUNX1(+) ALL, but the presence of a functional EPOR on the cell surface and its role in leukemogenesis driven by ETV6-RUNX1 remains to be identified.
|
21900195 |
2011 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism by which TEL-AML1 contributes to this early stage of leukemogenesis is unknown.
|
15155899 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression.
|
11483520 |
2001 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FISH analysis with the use of the YAC 936e2 probe, which covers the TEL gene, did not show the split signal, suggesting that a gene other than TEL was involved in the leukemogenesis of the present case.
|
10549263 |
1999 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that TEL-AML1 may contribute to leukemogenesis by recruiting N-CoR to AML1 target genes and thus imposing an altered pattern of their expression.
|
11001911 |
2000 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data infer that IGF2BP1 is a potent regulator of ETV6/RUNX1 mRNA stability and potentially link this evolutionary-highly conserved protein to cell transformation events in ETV6/RUNX1-mediated leukemogenesis of t(12;21)(p13;q22)-positive ALL.
|
26852652 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that breakage and fusion of TEL and AML1 may be relatively common events and that sublethal apoptotic signals could play a role in initiating leukemogenesis via the promotion of DNA damage.
|
11157492 |
2001 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the level of TEL expression can be important for leukemogenesis.
|
9671410 |
1998 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicated that TEL-MN1 fusion is an oncogene involved in the leukemogenesis process and TEL-MN1 overexpression enhanced resistance of HL-60 cells to idarubicin, which may provide a useful tool for studying the mechanism of leukemogenesis and drug resistance.
|
30840968 |
2018 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the ETV6 gene rearrangements in this case were apparently independent of contribution to leukemogenesis, because this cytogenetic aberration appeared as a secondary change.
|
12393285 |
2002 |